Shyeilla V. Dhuria
Publications by Year
Research Areas
Advanced Breast Cancer Therapies, Cell death mechanisms and regulation, HER2/EGFR in Cancer Research, Neuroendocrine Tumor Research Advances, Sleep and Wakefulness Research
Most-Cited Works
- → Intranasal delivery to the central nervous system: Mechanisms and experimental considerations(2009)1,205 cited
- → Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors(2014)208 cited
- → Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system(2008)133 cited
- → Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study(2016)132 cited
- → Novel Vasoconstrictor Formulation to Enhance Intranasal Targeting of Neuropeptide Therapeutics to the Central Nervous System(2008)99 cited
- → Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations(2017)78 cited
- → Ribociclib Drug‐Drug Interactions: Clinical Evaluations and Physiologically‐Based Pharmacokinetic Modeling to Guide Drug Labeling(2020)43 cited
- → Ribociclib (LEE011) and letrozole in estrogen receptor-positive (ER+), HER2-negative (HER2–) advanced breast cancer (aBC): Phase Ib safety, preliminary efficacy and molecular analysis.(2016)32 cited
- → A Phase 1, First-in-Human Study of AMG 176, a Selective MCL-1 Inhibitor, in Patients With Relapsed or Refractory Multiple Myeloma(2019)29 cited
- → Abstract 2775: A phase I study of LCL161, an oral IAP inhibitor, in patients with advanced cancer(2010)25 cited